ScreenerHero
YDESYD Bio Limited Ordinary Shares
NAS · US · Healthcare · Biotechnology · ydesgroup.com
4.480USD+0.22%Mkt Cap: 316.62M $P/E: —

YD Bio Limited a biopharmaceutical company focuses on blood-based cancer detection and develops stem cell- and exosome-based therapeutics to transform the treatment of spectrum of diseases with unmet medical needs. The c…

Industry Peers

Biotechnology
Screen all
VX1
Vertex Pharmaceuticals Incorporated
$130.23BUSDP/E 32.1
VRTX
Vertex Pharmaceuticals Incorporated
$139.84BUSDP/E 32.2
REGN
Regeneron Pharmaceuticals, Inc.
$85.11BUSDP/E 20.4
MRNA
Moderna, Inc.
$69.62BUSD
ARGX
argenx SE
$61.34BUSDP/E 39.8
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$46.01BUSD
ONC
BeOne Medicines AG
$41.76BUSDP/E 66.2
RPRX
Royalty Pharma Plc Class A
$35.67BUSDP/E 33.2
ALNY
Alnylam Pharmaceuticals, Inc.
$32.46BUSDP/E 42.3
INSM
Insmed Incorporated
$28.53BUSD
22UA
BioNTech SE
$26.14BUSD
INCY
Incyte Corporation
$25.79BUSDP/E 16.2
GMAB
Genmab A/S
$20.83BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$17.03BUSDP/E 20.0
BBIO
BridgeBio Pharma, Inc.
$16.41BUSD
EXEL
Exelixis, Inc.
$13.48BUSDP/E 17.1
BMRN
BioMarin Pharmaceutical Inc.
$13.42BUSDP/E 187.4
CORT
Corcept Therapeutics Incorporated
$12.87BUSDP/E 264.5
HeadlineSourceTime
Older
Breeze Holdings Acquisition (YDES) Rises 31% Over the Past Month

In recent events, YD Bio Limited's addition to the NASDAQ Composite Index has elevated the company's market standing, while Breeze Holdings Acquisition (YDES) has seen a 31% price rise over the past month. This surge coincides with significant developments, including a business combination with Taiwan-based YD Biopharma, signaling a move to strengthen their presence in the biopharmaceutical industry. These corporate actions place the company's recent performance against the backdrop of a...

Simply Wall St.
Top Midday Gainers

Professional Diversity Network (IPDN) said Friday it signed a non-binding memorandum of understandin

MMT Newswires